TITLE

Phase III of Rituxan in Leukemia Meets its Goal

PUB. DATE
October 2008
SOURCE
Bioworld Week;10/13/2008, Vol. 16 Issue 41, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article cites a study which shows that leukemia drug Rituxan from Genentech Inc. and Biogen Inc. passed a second Phase II study. It is stated that Rituxan combined with chemotherapy treatments fludarabine and cyclophosphamide improved progression-free survival in patients with previously treated CD20-positive chronic lymphocytic leukemia. According to Genentech, this study is the first to show an improvement in progression-free survival.
ACCESSION #
34835729

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics